A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer
Luigi Tarantini(Santa Maria Nuova Hospital), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Giuseppina Gallucci, Maria Pagano(Tecnologie Avanzate (Italy)), Giulia Alberti(Tecnologie Avanzate (Italy)), Andrea Camerini(Ospedale Versilia), Mario Larocca(Tecnologie Avanzate (Italy)), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Nicola Maurea(Cancer Institute (WIA)), Alessandro Navazio(Presidio Ospedaliero), Maria Laura Canale(Ospedale Versilia), Francesca Zanelli(Ospedale Santa Maria)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317